Cell therapy for T-cell malignancies—the science and business of developing curative medicines for patients in need

https://is1-ssl.mzstatic.com/image/thumb/Podcasts115/v4/7a/89/d2/7a89d2eb-58c2-8887-e394-e727c76dc72f/mza_5501671720659720569.jpg/600x600bb.jpg

Talking Precision Medicine

Genialis

51 episodes

15 hours ago

Welcome to the Talking Precision Medicine podcast. In this series, we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host.

Life Sciences

Science

RSS

All content for Talking Precision Medicine is the property of Genialis and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Life Sciences

Science

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded/1109085/1109085-1591869612639-da4fed0a60a7.jpg

Cell therapy for T-cell malignancies—the science and business of developing curative medicines for patients in need | Talking Precision Medicine #37

Talking Precision Medicine

39 minutes 1 second

1 year ago

Cell therapy for T-cell malignancies—the science and business of developing curative medicines for patients in need | Talking Precision Medicine #37

In this episode I chat with Dr Sarah Hein, co-founder and CEO of March Biosciences, a Houston Based biotech developing cell therapies for T-cell malignancies. Sarah is an old friend and colleague from our days as trainees at Baylor College of Medicine, where we both circulated among those with ambitions of entrepreneurship. Sarah has definitely made good in that regard, as a serial entrepreneur deeply enmeshed in Houston’s growing life sciences and healthtech ecosystem.

Episode 37 links: